BCRX Historical PE Ratio Notes

— BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing & commercializing innovative therapies for rare & serious diseases, particularly in the fields of immunology & rare blood disorders. Their flagship product, ORLADEYO™ (berotralstat), is an oral therapy approved for the prevention of hereditary angioedema (HAE) attacks. BioCryst's pipeline consists of additional experimental drugs targeting conditions with high unmet medical need. When reviewing BCRX's historical P/E ratio, it's important to understand that as a biotech firm with a history of significant research & development expenses and, until recently, limited product revenues, the company has often reported negative earnings per share (EPS). This results in either a very high P/E ratio or none at all in many periods, as the calculation is not meaningful with negative earnings. Historical P/E trends for BCRX primarily reflect the transition from pre-commercialization (reliant on future drug approvals & milestones) to one where it is generating sales from its own marketed products. Investors should be aware that volatility in P/E history can be attributed to shifts in earnings expectations, regulatory milestones, & the market's evolving view of future profitability.

On this page we presented the BCRX Historical PE Ratio information for BioCryst Pharma' stock. The average BCRX historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 21.7. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average BCRX historical PE based on this TTM earnings result method is 22.8. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this BCRX historical PE result, against the recent PE: when this page was posted on 8/5/2026, the most recent closing price for BCRX had been 9.07, and the most recent quarterly earnings result, annualized, was 1.2. Meanwhile, the most recent TTM earnings summed to 0.655. From these numbers, we calculate the recent BCRX PE on 8/5/2026 based on annualized quarterly EPS was 7.6. Based on BCRX's history, that recent PE is low relative to the historical average, with the recent PE 65.0% lower than the historical average PE across our data set for BioCryst Pharma. Looking at the recent BCRX PE on 8/5/2026 based on TTM EPS, we calculate the ratio at 13.8. Based on BCRX's history, that recent PE is low relative to the historical average, with the recent PE 39.5% lower than the average PE across our BioCryst Pharma data set with TTM EPS used in the calculation at each period.

Another interesting BCRX historical PE Ratio calculation we look at is to take the median earnings per share of the last four quarters for BCRX, and then annualize the resulting value... with that annualized number then being used in the PE calculation. To walk through this math for BCRX, we start with the past four EPS numbers and we first sort them from lowest to highest: 0.06, 0.14, 0.16, and 0.30. We then toss out the highest and lowest result, and then take the average of those two middle numbers — 0.14 and 0.16 — which gives us the median of 0.15. Basically the way to think about this 0.15 number is this: for the trailing four earnings reports, 0.15 marks the "middle ground" number where BCRX has reported a value higher than 0.15 half the time, and has reported a value lower than 0.15 half the time. Annualizing that median value then gets us to 0.6/share, which we use as the denominator in our next PE calculation. With 9.07 as the numerator (as of 8/5/2026), the calculation is then 9.07 / 0.6 = 15.1 as the BCRX PE ratio as of 8/5/2026, based on that annualized median value we calculated.

For self directed investors doing their due diligence on BCRX or any other given stock, valuation analysis for BCRX can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate BioCryst Pharma PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for BCRX. Thanks for visiting, and the next time you need to research BCRX Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.